Bachem : launches accelerated bookbuilding for approx. 750k new shares
October 18, 2021 at 12:02 pm EDT
Share
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.
Bachem launches an accelerated bookbuilding for the placement of approx. 750'000 new shares to finance its growth plan
Share placement of approx. 750'000 new shares via an accelerated bookbuilding authorized by the extraordinary general shareholder meeting held on October 15, 2021, and representing approx. 5% of currently issued share capital.
Bachem intends to deploy the funds to accelerate capacity expansion across all sites and the construction of an additional manufacturing site in Switzerland.
Upon completion, the capital increase will enhance the trading liquidity of Bachem shares and expand the shareholder base.
About Bachem
Bachem is a leading, innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides.
With 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services.
Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia. The company is listed on the SIX Swiss Exchange.
Press release in English
Press release in German
For more information:
Bachem Holding AG
Dr. Daniel Grotzky
Head Group Communications
Bachem Holding AG published this content on 18 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 18 October 2021 16:01:02 UTC.
Bachem Holding AG is a Switzerland-based biochemical company that provides services to the pharmaceutical and biotechnology industry. The Company focuses on the process development and manufacturing of peptides and organic molecules as active pharmaceutical ingredients (APIs), as well as on the development of biochemical products for research purposes. Its product portfolio comprises fluorescent dyes for the fluorescence energy transfer (FRET) analysis of receptor-ligand interactions, protein-protein interactions and the cleavage of substrate molecules, as well as glycosylated peptides for the manipulation of drug properties. The Company markets products under the Bachem and Clinalfa brands and operates production facilities in Switzerland and in the United States.